BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Cellzome AG Builds Scientific Advisory Board with World-Leading Experts in Proteomics, Epigenetics and Immunology


2/23/2011 9:53:33 AM

Heidelberg, Germany, Cambridge, UK 23rd February 2011 – Cellzome announces the appointment of four new members to its Scientific Advisory Board (SAB), further extending its scientific network in immunology, epigenetics and proteomics.

Joining the team are Professors Ruedi Aebersold; Anne Ferguson-Smith; Jeannie Lee and Diane Mathis. The announcement follows the appointment of Prof. Tony Kouzarides and Dr. Peter Machin in October last year.

David Simmons, CSO of Cellzome and chairman of the SAB said, “We are delighted to have been able to bring together the top scientists from the different disciplines on our SAB. This network of excellence will further stimulate our science and drug discovery programmes.”

Prof. Ruedi Aebersold is a pioneer in the field of proteomics. He developed a series of methods that have found wide application in this field, including methods to enable reliable protein quantification by mass spectrometry. He served as faculty member of the Universities of Washington and British Columbia and in 2000 co-founded the Institute for Systems Biology in Seattle. Most recently, he co-founded the Institute of Molecular Systems Biology at the ETH in Zurich where he is a full professor.

Prof. Anne Ferguson-Smith has established an international reputation for her work integrating the epigenetic control of genome function with developmental and physiological processes relevant to health and disease. She has more than two decades of experience in the exploration of links between gene regulation, large and small non-coding RNAs and epigenetic modifications, and the consequences of perturbations in these interactions for pre and postnatal well-being. She is Professor of Developmental Genetics at the University of Cambridge and contributes to a range of national and international review panels and initiatives at the interface of genomic and epigenomics research.

Prof. Jeannie Lee is an Investigator of the Howard Hughes Medical Institute and Professor of Genetics (and Pathology) at Harvard Medical School and the Massachusetts General Hospital. Since she became independent in 1997, her lab's interests have included X-inactivation, imprinting, the emerging link between noncoding RNA and chromatin control, and the evolutionary history of sex chromosomes and dosage compensation.

Prof. Diane Mathis is a Professor of Pathology at Harvard Medical School, a Principal Faculty member of the Harvard Stem Cell Institute and an Associate Member at the Broad Institute. Her laboratory works in the fields of T-cell differentia¬tion and autoimmunity, with a special emphasis on exploiting the most advanced transgenic and gene-targeting technologies.

The four distinguished scientists join Professors Christopher Buckley, Sir Philip Cohen, Tony Kouzarides, David Sabatini, Giulio Superti-Furga, Arthur Weiss and Dr. Peter Machin on the Cellzome SAB, representing a global network of scientific excellence.

For full biographies of the Cellzome SAB please see: www.cellzome.com/sab.html

For more information please contact:

Cellzome: Tim Edwards Chief Executive Officer Tel: +49 (0) 6221-137 57-100 press@cellzome.com

Media contact: Nicole Yost, Jayne Crook College Hill Tel: +44 (0)20 7866 7862 cellzome@collegehill.com

About Cellzome

Cellzome is a world leader in chemoproteomics, transforming the sciences of epigenetics and signal transduction into novel drug candidates in inflammatory diseases and oncology. The Company maintains the highest levels of scientific expertise and has active collaborations with the foremost academic laboratories around the world. Cellzome’s technologies work with native proteins in a physiological setting to discover small molecule drugs targeting protein complexes that underlie diseases. The Company has a track record in delivering significant collaborations with top pharmaceutical companies including GlaxoSmithKline, Johnson & Johnson and Novartis. Cellzome is a privately-held, international, company located in Heidelberg, Germany and Cambridge, UK employing about 100 people. For more information please visit: www.cellzome.com


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->